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ABSTRACT
It is well recognized that Cancer Stem Cells (CSCs) sustain the initiation, the 
maintenance and the recurrence of tumors. We previously reported that extracellular 
vesicles (EVs) derived from human liver stem cells (HLSCs) were able to limit tumor 
development. In this study, we evaluated whether EV derived from HLSCs could act in 
synergy with tyrosine kinase inhibitors (TKIs) on apoptosis of CSCs isolated from renal 
carcinomas. For this purpose, we administered to renal CSCs, HLSC-EVs and TKIs, as co-
incubation or sequential administration. We found that HLSC-EVs in combination with 
Sunitinb or Sorafenib significantly increased renal CSCs apoptosis induced by low TKI 
dose. At variance, no synergistic effect was observed when bone marrow mesenchymal 
stem cell-derived EVs were used. In particular, renal CSCs chemosensitivity to TKIs 
was enhanced when HLSC-EVs were either co-administered with TKIs or added after, 
but not before. CSC apoptosis was also incremented at a percentage comparable to 
that of co-administration when TKIs were loaded in HLSC-EVs. By a mechanistic point 
of view, Akt/mTOR and Erk and Creb intracellular pathways, known to be pivotal in the 
induction of tumor growth and survival, appeared modulated as consequence of TKIs/
HLSC-EVs co-administration. Together, our results indicate that the synergistic effect 
of HLSC-EVs with TKIs may increase the response to TKIs at low doses, providing a 
rational for their combined use in the treatment of renal carcinoma.
INTRODUCTION
Renal cell carcinoma (RCC) is a common solid 
tumour associated to high mortality with frequent 
metastatic spread and high recurrence within 5 years [1]. 
Therapy for RCC is based on tumor surgical resection, as 
this tumor is highly resistant to common chemotherapeutic 
drugs [2, 3]. Over the last decade, a group of tyrosine 
kinase inhibitors (TKIs) was introduced in the clinical 
practice as first line treatment for metastatic RCC. 
Their anticancer activity is related to the inhibition of 
growth factor receptors overexpressed in renal cancer 
and responsible, at least in part, for tumor angiogenesis 
and cell proliferation [4]. Among TKIs, Sunitinib, and 
Sorafenib have conferred a good clinical outcome of 
patients in term of response rate, progression-free survival 
and overall survival [5]. Despite the clinical benefits, TKIs 
also display several adverse events such as hand-foot 
www.oncotarget.com                               Oncotarget, 2018, Vol. 9, (No. 90), pp: 36151-36165
           Research Paper
Oncotarget36152www.oncotarget.com
syndrome, mucosal inflammation, hypothyroidism and 
fatigue, together with hematological adverse events like 
anemia, leukopenia and thrombocytopenia [6]. Moreover, 
a major limit of TKI long-term anti-tumor effect is the 
development of resistance in the vast majority of cases [7].
It is now well recognized that the initiation, 
the maintenance and the recurrence of tumors is 
sustained by Cancer Stem Cells (CSCs), a small cell 
population with stem-like properties identified in 
several solid tumors [8–10]. In particular, in RCC, a 
CSC population has been identified by expression of 
surface endoglin (CD105) [11–15]. These renal CSC 
were shown to display several typical characteristics 
for cancer stem cells/tumor initiating cells, including 
clonogenicity, expression of stem cell markers and 
absence of differentiation markers, in vitro epithelial and 
endothelial differentiation ability, and generation of in 
vivo serially transplantable tumors with characteristics 
similar to the tumor of origin [11]. In consideration of 
the high drug resistance and tumor initiating capability 
of renal CSC, their targeting represents an important 
approach to eradicate RCC.
Cell-to-cell interaction is at least in part orchestrated 
by extracellular vesicles (EVs) that play a key role in cell 
communication by transferring mRNA, microRNA, lipids 
and proteins to target cells [16–18]. Tumor derived EVs 
were found to modulate tumor interstitial cell interaction 
and metastatic spread [19]. On the other hand, it was found 
that EVs derived from stem cells are able to reprogram 
tumor cells to a more benign phenotype, exerting their 
anti-tumor effect by blockade of proliferation and 
induction of apoptosis in vitro and by the regression of 
ectopic tumors in vivo [20, 21]. This anti-tumor activity 
was particularly evident for EVs derived from human liver 
stem cells (HLSC), a stromal cell population isolated from 
human adult liver that inhibited liver carcinomas as well as 
gliomas and lymphoblastomas [22].
In the present work, we investigated whether HLSC-
EVs were able to exert an inhibitory effect in vitro on renal 
CSCs and to enhance the pro-apoptotic effect of TKIs, in 
different combination settings.
RESULTS
Co-administration of HLSC-EVs and TKIs 
increase apoptosis of rCSCs
Renal CSCs were isolated from renal carcinoma 
by magnetic cell sorting using selection for the CD105 
surface antigen, and characterized as previously described 
[11]. Renal CSCs fulfilled the criteria of CSCs, including 
clonogenicity, expression of stem cell markers and 
generation of in vivo serially transplantable tumors (See 
Material and Methods and Supplementary Figure 1). To 
test the effect of stem cell derived EVs on chemosensitivity 
of renal CSCs, we isolated EVs from HLSC (HLSC-
EVs) by ultracentrifugation. EVs were analyzed by 
NanoSight to quantify particle number and size (Figure 
1A). Moreover, they were characterized by Western blot 
analysis for the expression of their characteristic markers 
CD63 and CD81 and by electron microscopy for their 
round cup-shape morphology (Figure 1B and 1C), as 
described [23]. When incubated with G7 renal CSCs, 
HLSC-EVs labelled with DIL dye were internalized by 
tumor cells after 1 hour of incubation at 37°C, as shown 
in Figure 1D. These characteristics are similar to those 
described for EVs derived by mesenchymal stromal cells 
(MSC-EVs) [23].
The effect of EVs on CSC apoptosis was evaluated 
after treatment of different doses (5, 10, 50 × 103 EV/
target cell) of HLSC-EVs and MSC-EVs. As shown in 
Figure 2A, HLSC-EVs, but not MSC-EVs, exerted a 
dose dependent pro-apoptotic effect on G7 renal CSC 
that was statistically significant at the dose of 50 × 103 
EV/target cell (Figure 2A). In order to evaluate a possible 
combinatory effect of EVs with Sunitinib, we first 
performed experiments to evaluate the TKI dose-response 
on renal CSCs (Supplementary Figure 2A). We selected 
the dose of Sunitinib showing the minimal pro-apoptotic 
effect (1 μM; Supplementary Figure 2). The percentage 
of renal CSC apoptosis was significantly increased when 
HLSC-EVs were co-administered with 1 μM Sunitinib 
compared to Sunitinib alone as well as to HLSC-EVs 
alone, as evaluated by Annexin V Dead Cell Assay and by 
Annexin V immunofluorescence staining (Figure 2B, 2E-
2H). In particular, an increment of about 40% of apoptosis 
was observed already at the low non-apoptotic dose of 
5 × 103 HLSC-EVs/target cell in combination with 1 μM 
Sunitinib (Figure 2B).
In order to test whether the apoptotic effect was 
specific for Sunitinib or common to other TKIs used for 
the treatment of metastatic RCC, we also tested Sorafenib 
and Cabozantinib alone and in combination with HLSC-
EVs. The minimal apoptotic dose of 5 μM was used for 
Sorafenib (Supplementary Figure 2B) and of 2 μM for 
Cabozantinib (Supplementary Figure 2C). Figure 2 shows 
that both the Sorafenib/HLSC-EVs and Cabozantinib/
HLSC-EVs co-administration induced an enhancement 
of apoptotic cells, with a similar effect to the Sunitinib/
HLSC-EVs co-administration. Moreover, this increment 
was significant not only in respect to control cells, but 
also to cells stimulated with HLSC-EVs or TKIs alone 
(Figure 2C).
Finally, to evaluate whether the observed effect on 
chemosensitivity was specific for renal CSCs or could 
be shared by CSCs of different origin, the effect of 
HLSC-EVs and Sunitinib/Sorafenib/Cabozantinib co-
administration was evaluated also on C10 breast CSCs. 
The results showed a significant apoptotic increment 
similar to that observed for renal CSCs (Figure 2D).
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Pro-apoptotic effect of HLSC-EVs loaded 
with TKIs
To assess whether the pro-apoptotic effect of HLSC-
EV/TKI co-administration could be further increased using 
TKI-loaded EVs, we generated HLSC-EVs loaded with 
Sunitinib or Sorafenib. As these TKIs are lipophilic [24], 
we simply co-incubated EVs with TKIs for 15 minutes 
followed by ultracentrifugation to wash out the unbound 
drugs. The EVs obtained were called EV-SUN or EV-
SOR to indicate EVs loaded with Sunitinib or Sorafenib 
respectively. The effective drug loading within EVs was 
determined by spectrum analysis (see Mat and Methods) 
and the amount of EVs was calculated in order to reach 
the same TKI concentration used in experiments above. As 
shown in Figure 3, the pro-apoptotic effect of HLSC-EVs 
loaded with TKIs was comparable to that of HLSC-EVs 
and TKIs co-administration (Figure 3), suggesting that that 
drug-loaded EVs could be an alternative approach for drug 
delivery.
Figure 1: Characterization of EVs isolated from HLSCs. (A) NanoSight size distribution graph showing the quantity and size 
of HLSC-EVs. (B) Representative Western blot analysis of CD63 and CD81 protein expression in HLSC-EVs. Data represent one of 
two experiments with similar results. (C) Representative electron microscopy of HLSC-EVs (scale bar = 100 nm). (D) Incorporation 
of DIL-labelled HLSC-EVs in G7 renal cells after 1 hour of incubation detected by confocal microscopy by z stack program (Original 
magnification x400).
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Figure 2: Apoptotic effect of HLSC-EVs on renal and breast CSCs. (A) Analysis of apoptosis of G7 renal CSCs induced by 
different doses of HLSC-EVs (black column) and BM derived MSC-EVs (white column). G7 renal CSCs were stimulated for 48 hours with 
different doses of HLSC-EVs or MSC-EVs and Muse Annexin V & Dead Cell Assay evaluated apoptotic cells. (B) Apoptosis analysis of 
G7 renal CSCs stimulated with 1μM of Sunitinib alone and in combination with different doses of HLSC-EVs (5, 10, and 50 x 103 EVs/
target cells) for 48 hours. Data are mean ± SD of five different experiments (A and B): *= p < 0.05 vs CTL cells; # = p < 0.05 vs Sunitinib. 
(C) Apoptosis analysis of G7 renal CSCs evaluated after 48 hours of treatment with HLSC-EVs (50 x 103 EVs/target cells), Sunitinib 
(1μM), Sorafenib (5μM) and Cabozantinib (2μM) alone or in combination (HLSC-EVs+Sun, HLSC-EVs+Sor, HLSC-EVs+Cabo). (D) 
Apoptosis analysis of C10 breast CSCs stimulated for 48 hours with HLSC-EVs (50 x 103 EVs/target cells), Sunitinib (1μM), Sorafenib 
(5μM) and Cabozantinib (2μM) alone or in combination (HLSC-EVs+Sun, HLSC-EVs+Sor, HLSC-EVs+Cabo). Data are mean ± SD of 
three different experiments (C and D): *= p < 0.05 vs CTL; # = p < 0.05 vs HLSC-EVs; § = p < 0.05 vs Sunitinib; @ = p < 0.05 vs Sorafenib; 
^ = p < 0.05 vs Cabozantinib. (E-H) Representative cytofluorimetric analysis of dead and apoptotic cells as evaluated by Muse™ Annexin 
V and Dead Cell Assay and immunofluorescence images of Annexin V staining of renal CSCs when treated with HLSC-EV, Sunitinib alone 
or their combination. Nuclei are stained with Hoechst 33342 (blu). (Original magnification x400).
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HLSC-EVs co-administered with TKIs inhibited 
the Akt/mTOR/PTEN pathway
In order to understand the mechanism underlying 
the pro-apoptotic effect exerted by co-administration 
of TKIs and HLSC-EVs, we performed a Bio-Plex Pro 
cell signaling assay for the detection of intracellular 
phosphoproteins (not shown). The results were then 
validated by Western blot analysis. As shown in Figure 
4, we found that TKIs and HLSC-EVs co-administration 
induced a synergistic effect in respect to TKIs or 
EVs alone on specific pathways. In particular, the co-
administration of Sunitinib and HLSC-EVs was able 
to reduce Akt activity and enhance the oncosuppressor 
PTEN trough decrease of its phosphorylated form in 
respect to treatments alone (Figure 4A and 4B). The Akt/
PTEN pathways was inhibited also by co-administration 
of Sorafenib and HLSC-EVs, even if the reduction of 
pPTEN/PTEN ratio did not reach significance (Figure 
4A and 4B). In addition, we found that the PTEN protein 
was directly expressed by HLSC-EVs (Figure 4B, inset). 
Moreover, HLSC-EVs alone significantly reduced the 
active phosphorylated form of mTOR (Figure 4C) and the 
activation of the Creb transcription factor (Figure 5A and 
5B).
Finally, the Sorafenib/HLSC-EV co-administration 
induced a significant decrease of Erk 1/2 (Figure 5C) that 
was specific for this TKI, as no synergistic effect was 
observed with Sunitinib/HLSC-EV (Figure 5C).
EV post-incubation but not pre-incubation 
increase chemosensitivity
We also performed experiments of sequential 
administration of HLSC-EVs and TKIs to better dissect 
the synergistic effect of EVs on TKI induced apoptosis. 
We first incubated renal CSCs with HLSC-EVs for 8 hours 
and then stimulated with Sunitinib (1 μM) or Sorafenib (5 
μM) for additional 40 hours, to reach 48 hour incubation 
used in co-administration experiments (Figure 6A). On the 
other hand, we incubated renal CSCs with Sunitinib or 
Sorafenib for 40 hours and then stimulated with HLSC-
EVs for additional 8 hours (Figure 6A). The results 
indicated that only the post- incubation and not the pre-
incubation of HLSC-EVs enhanced the chemosensitivity 
of renal CSCs to TKIs (Figure 6B). This further 
suggests that the effect of HLSC-EVs/TKI combination 
on chemosensitivity was due to an EV-dependent 
enhancement of TKI induced mechanisms and not to 
epigenetic changes induced by EV leading to increased 
Figure 3: Effect of loading of HLSC-EVs with TKIs on G7 renal CSCs apoptosis. Apoptosis analysis of G7 renal CSCs treated 
with Sunitinib, Sorafenib, or with HLSC-EVs loaded with Sunitinib (EV-SUN) or with Sorafenib (EV-SOR). The supernatant (surn-SUN 
and surn-SOR) after ultracentrifugation was recovered used as negative control. Data are mean ± SD of three different experiments: *= p < 
0.05 vs CTL; # = p < 0.05 vs HLSC-EVs; § = p < 0.05 vs Sunitinib; @ = p < 0.05 vs Sorafenib.
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Figure 4: HLSC-EVs/TKIs co-administration decreased phospho-proteins in renal CSCs. Western blot micrograph and 
densitometric analysis of pAkt/Akt (A), pPTEN/PTEN (B) and p-mTOR/mTOR (C) ratio on G7 renal CSCs stimulated for 3 hours with 
HLSC-EVs (50 x 103 EVs/target cells), Sunitinib (1μM), Sorafenib (5μM) alone or in combination (HLSC-EVs+Sun, HLSC-EVs+Sor). 
Data, shown as arbitrary units, were representative of three different experiments and were normalized to vinculin expression. *= p < 0.001 
vs CTL. Inset: Western blot micrograph of PTEN expression by HLSC-EVs.
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TKI sensitivity. This notion was supported by the analysis 
of the p-AKT/p-mTOR and PTEN pathways of renal 
CSCs pre- or post-treated with EVs. Indeed, a significant 
additive effect of EVs in reducing the phosphorylation of 
Akt/mTOR pathway was observed only when EVs were 
administered after Sorafenib (Figure 6C-6E).
Altogether, these results, summarized in Figure 7, 
indicate that EVs synergize with TKI in inducing apoptosis 
by interfering with renal CSC survival pathways.
DISCUSSION
In this study, we demonstrate a specific synergistic 
effect of HLSC-EVs with TKIs in inducing apoptosis 
of renal and breast CSCs. In particular, renal CSCs 
chemosensitivity to TKIs was enhanced when HLSC-
EVs were co-administered or sequentially added after 
TKIs. The observed effect can be ascribed to a combined 
modulation of the Akt/mTOR and Erk survival pathways 
by HLSC-EV/TKI co-administration.
Renal cell carcinoma is considered one of the 
fastest increasing cancers over the next 20 years. Every 
year, 63,920 [25] and 115,200 [26] estimated new cases 
of kidney cancer in the United States and in Europe, 
respectively, are registered with estimate death cases of 
13,860 and 49,000. Nowadays, a group of TKIs, which 
comprises Sunitinb and Sorafenib, represents the first 
line treatment for metastatic RCC [27]. Unfortunately, 
the TKI-based therapy is often correlated with several 
adverse effects and with development of resistance [28], 
highlighting the importance to improve the benefit of the 
TKIs limiting the related complications.
Several groups showed an anti-tumor activity by 
bone marrow MSC-EVs and placental stem cell-derived 
EVs [20, 29–32]. We here showed that, as reported for 
other tumor cell types, [22], HLSC-derived EVs, induced 
a significant degree of apoptosis in renal CSCs. No effect 
of MSC-EVs was observed in this model. Interestingly, 
we found that HLSC-EVs directly modulated CSC 
intracellular pathways (Akt, mTOR and Creb), in analogy 
Figure 5: HLSC-EVs inhibited pCreb/Creb ratio and, when combined with Sorafenib, Erk 1/2. Western blot micrograph 
and densitometric analysis of pCreb/Creb ratio (A and B) and of Erk 1/2 (C) on G7 renal CSCs stimulated for 3 hours with HLSC-EVs 
(50 x 103 EVs/target cells), Sunitinib (1μM), Sorafenib (5μM) alone or in combination (HLSC-EVs+Sun, HLSC-EVs+Sor). Data, shown 
as arbitrary units, were representative of three different experiments and were normalized to vinculin expression. *= p < 0.001 vs CTL.
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Figure 6: Effect of HLSC-EVs and TKIs sequential administration on G7 renal CSCs apoptosis. (A) Schematic 
representation of the sequential administration experiment. Pre-EVs: G7 renal CSCs were incubated with HLSC-EVs for 8 hours and then 
stimulated with Sunitinib (1 μM) or Sorafenib (5 μM) for additional 40 hours. Post-EVs: G7 renal CSCs were stimulated with Sunitinib 
or Sorafenib for 40 hours and then stimulated with HLSC-EVs for additional 8 hours for a total of 48 hours of incubation. (B) Apoptosis 
analysis of G7 renal CSCs after 48 hours of sequential treatment. Data are mean ± SD of three different experiments: *= p < 0.05 vs CTL; # 
= p < 0.05 vs HLSC-EVs; § = p < 0.05 vs Sunitinib; @ = p < 0.05 vs Sorafenib. (C-E) Western blot micrograph and densitometric analysis 
of pAkt/Akt (C), p-mTOR/mTOR (D) and pPTEN/PTEN (E) ratioon CSCs after sequential administration of HLSC-EVs (3 hours) and 
Sorafenib (40 hours). Data, shown as arbitrary units, were representative of three different experiments and were normalized to vinculin 
expression: *= p < 0.001 vs CTL.
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with the reported effect of MSC-EVs on the direct 
modulation of protein FAK phosphorylation in myeloma 
cells [33]. Moreover HLSC-EVs contained PTEN that 
could be possibly transferred to the target CSCs. Indeed, 
transfer of signalling molecules packaged into exosomes 
[34] was also reported for tumor exosomes.
We also found that when HLSC-EVs were combined 
with Sunitinib at a minimally affecting dose (1 μM), the 
percentage of renal CSC apoptosis was significantly 
increased compared to Sunitinib alone as well as to HLSC-
EVs alone. The increase was of particular evidence (about 
40% increase of apoptosis) at the lowest non-apoptotic 
dose of HLSC-EVs when combined with Sunitinib. These 
results appear of interest for improving the effect of TKIs, 
as they were common to different drugs and to CSC from 
other tumors. In fact, HLSC-EVs showed a synergic 
effect when co-administered also with Sorafenib and 
Cabozantinib. Moreover, the combination of HLSC-EVs 
with different TKIs was effective not only on renal CSCs, 
but also on breast CSCs, supporting the hypothesis that the 
combination of EVs with anti-cancer drugs could be useful 
in clinical application to treat tumors of numerous origin. 
in vivo experiments of synergistic administration would 
be required to confirm this effect. Indeed, EVs present 
several advantages as possible therapeutic tools [35, 36] as 
they possess a high biocompatibility and can easily diffuse 
through tissue due to their small size.
In the attempt to identify possible strategies for 
a clinical administration, we performed experiments 
of sequential administration that indicated a benefit 
when EVs were added after TKIs. This may suggest 
that EVs may act of CSCs by enhancing TKI induced 
mechanisms rather than by inducing epigenetic changes 
and leading to increased TKI sensitivity. This appears 
a different mechanism in respect to that observed for 
cancer treatment with normal prostate cell-derived EVs 
that reverted paclitaxel resistance [37]. An alternative 
strategy for EV and TKI administration can be envisaged 
Figure 7: Survival pathways modulated by HLSC-EVs/TKIs co-administration. Schematic representation of the inhibitory 
effect of HLSC-EVs and of TKIs alone or in combination on PI3K pathway and Erk. In particular, the co-administration of HLSC-EVs/
TKIs exerted a synergistic effect (orange bars) on the inhibition of Akt and mTOR pathways and on pPTEN. HLSC-EVs alone (red bars) 
showed an inhibitory effect on Akt, mTOR pathways and on transcription factor Creb. Sunitinib or Sorafenib alone (yellow bars) inhibit 
RAS and mTOR pathways.
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in the direct EV loading with TKIs. HLSC-EVs loaded 
with Sunitinib and Sorafenib enhanced rCSC apoptosis 
in a similar manner to that of co-administration. These 
results confirmed that EVs may represent an alternative 
therapeutic drug delivery carrier not only for their specific 
homing ability but also for their higher loading ability 
to hydrophobic chemical drug in respect to liposomes 
[38, 39].
The mechanism responsible for the anticancer 
effect of TKIs mainly involve a negative regulation of 
the survival and proliferative intracellular pathways 
related to target growth factor receptor activation. The 
Phosphoinositide 3-kinase (PI3K)/AKT/mTOR and Ras/
Mek/Erk have been demonstrated as the most critical cell 
signalling pathways in carcinogenesis and display a cross 
talk between them [40]. In particular, PI3K/Akt/mTOR 
pathway modulates cell proliferation, survival, motility, 
invasion allowing cancer initiation and progression 
[41]. In addition, the MAPK pathway also regulates cell 
proliferation, growth, and survival [42]. We here found 
that HLSC-EVs alone modulated the classical targets 
of TKIs, and that the combination of EVs and TKIs 
further increased the observed effects. In fact, HLSC-
EVs alone displayed a negative effect on mTOR. The 
co-administration of HLSC-EVs with both Sunitinib 
and Sorafenib induced a reduction of phospho-Akt and 
phospho-mTOR, blocking their pro-survival activity. 
Moreover, the HLSC-EV/TKI treatment modulated the 
onco-suppressor PTEN, which in turn controls the PI3K/
Akt signalling pathway [43]. In particular, HLSC-EVs/
TKIs treatment induced a reduction of phospho-PTEN, 
the inhibitory form of PTEN, with resulting increase of 
its level and activity. This effect may be relevant for the 
control of CSCs, as the increase of p-PTEN/PTEN ratio 
sustains the acquisition of malignant phenotypes for 
many types of cancer [44]. Furthermore, the combination 
treatment of HLSC-EVs with Sorafenib induce an 
inhibition of Erk.
The effect of TKI/EV combination on the PI3K/
AKT/mTOR and Ras/MEK/ERK is confirmed by 
a significant decrease of the levels of pCreb, the 
transcription factor involved in their signalling to promote 
tumor growth, apoptotic resistance, angiogenesis, and 
distant metastasis [45]. In particular, EVs alone showed 
a significant decrease of pCreb that was further reduced 
when rCSCs were stimulated with a combination treatment 
of HLSC-EVs/Sunitinib.
Together, our results indicated that HLSC-EVs and 
TKIs have a synergistic anti-tumor effect on renal CSCs 
inducing an enhancement of apoptosis by a combined 
effect on Akt/mTOR, Erk and Creb intracellular pathways, 
known to be pivotal in the induction of tumor growth and 
survival. The synergistic effect of HLSC-EVs with TKIs at 
low doses may increase the response to TKIs on CSCs and 
provide a rational for a combined use of these products in 
the treatment of renal carcinoma.
MATERIALS AND METHODS
Cancer stem cells isolation and culture
Renal CSCs were isolated and characterized 
as previously described [11, 46]. Briefly, CSCs were 
obtained from specimens of renal cell carcinomas from 
patients undergoing radical nephrectomy according to the 
Ethics Committee of the S. Giovanni Battista Hospital 
of Torino, Italy (168/2014). Cells were isolated, using 
anti-CD105 Ab coupled to magnetic beads, by magnetic 
cell sorting using the magnetic-activated cell sorting 
(MACS) system (Miltenyi Biotec, Auburn, CA, USA) 
from renal carcinomas (histological types: 3 clear-cell 
type and 2 undifferentiated carcinomas). Briefly, cells 
were labelled with the anti-CD105 mAb for 20 min, 
washed twice and resuspended in MACS buffer (PBS 
without Ca2 and Mg2, supplemented with 1% BSA and 
5 mM EDTA) at a concentration of 2x107 cells. After 
washings, cells were separated on a magnetic stainless 
steel wool column (Miltenyi Biotec), according to the 
manufacturer’s recommendations. Magnetically sorted 
CD105+ CSCs were cultured in the presence of the 
expansion medium, consisting of DMEM LG (Invitrogen), 
with insulin-transferrin-selenium, 10-9 M dexamethasone, 
100 U penicillin, 1000 U streptomycin, 10 ng/ml EGF 
(all from Sigma-Aldrich) and 5% fetal calf serum (FCS) 
(Sigma-Aldrich). For cell cloning, single cells were 
seeded in 96-well plates in presence of the expansion 
medium. A G7 CD105+ clonal renal cell carcinoma stem 
cell line was selected and used for all the experiments. 
Immunophenotypic analysis showed the positivity for 
CD105, expression of the mesenchymal stem cell marker 
CD73, SSEA4 and the absence of CD133 and CD24 and 
EPCAM (Supplementary Figure 1A). When cultured in 
non-adhesive culture conditions, G7 renal CSCs were 
able to growth and form spheres that could be propagated 
for several passages (Supplementary Figure 1B). In vivo, 
when implanted subcutaneously in SCID mice, G7 renal 
CSC were able to generate tumors using a low number 
of cells, such as 1×103 and 1×102 cells (Supplementary 
Figure 1C). Moreover, CD105+ cells isolated from 
tumors were re-injected in SCID mice and gave raise to 
secondary and tertiary tumors (Supplementary Figure 1D), 
confirming their identity as tumor-initiating cells.
Breast CSCs were isolated from breast lobular-
infiltrating carcinoma obtained as previously described 
[47]. Briefly, tumour specimen was finely minced with 
scissors and digested by incubation for 1 h at 37°C in 
DMEM containing collagenase II (Sigma Chemical 
Company, St. Louis, MO, USA). After washings in 
medium plus 10% FCS (GIBCO, Grand Island, NY, USA), 
the cell suspension was forced through a graded series 
of meshes to separate the cell components from stroma 
and aggregates and, finally, through a 40-μm pore filter 
(Becton Dickinson, San Jose, CA, USA). Single cells 
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were plated at 1000 cells/ml in serum-free DMEM-F12 
(Cambrex BioScience, Venviers, Belgium), supplemented 
with 10 ng/ml basic fibroblast growth factor (bFGF), 20 
ng/ml epidermal growth factor (EGF), 5 (μg/ml insulin 
and 0.4% bovine serum albumin (all from Sigma), as 
described by Ponti et al. [48]. For cell cloning, single cells 
were seeded in 96-well plates in presence of the expansion 
medium. A C10 clonal breast cell carcinoma stem cell 
line (C10 breast CSCs) was selected and used for all the 
experiments.
Human mesenchymal and liver stromal 
stem cells
HLSC were isolated from human cryopreserved 
normal hepatocytes obtained from Lonza (Basel, 
Switzerland, https://www.lonza.com/), characterized and 
cultured as previously described [49, 50]. Human 
hepatocytes were plated in the presence of alfa minimum 
essential medium/endothelial cell basal medium 
(expansion media: ɑMEM/EBM in the ratio 3:1, Lonza), 
supplemented with antibiotics (100 U penicillin and 
1,000U streptomycin; both from Sigma, St. Louis) and 
10% Foetal Calf Serum (FCS, Sigma). After 2 week HLSC 
colonies were evident were expanded.
Bone marrow-derived mesenchymal stem cells 
(MSCs) were obtained from Lonza and cultured and 
characterized as previously described [51]. MSCs were 
used up to the sixth passage of culture. All of the cell 
preparations used were positive for the typical MSC 
markers (CD105, CD29, CD73, CD44, and CD90 (not 
shown)).
EVs isolation
The supernatant of HLSCs or MSCs was recovered 
and centrifuged for 20 min at 3000 g to remove cell debris 
and apoptotic bodies. An ultracentrifugation at 100,000 g 
for 2 hours at 4 °C (Beckman Coulter Optima L-90 K, 
Fullerton, CA, USA) has followed the previous one. Both 
HLSC-EVs and MSC-EVs were resuspended in RPMI 
supplemented with 1% dimethyl sulfoxide (DMSO) and 
frozen at –80 °C for later use. Concentration and size 
distribution of EVs were determined by the Nanosight 
LM10 system (NanoSight, Wiltshire, UK). Briefly, EV 
preparations were diluted (1:200) in sterile saline solution 
and analyzed by the Nanoparticle Analysis System using 
the NTA 1.4 Analytical Software (Figure 1A) [52]. To 
evaluate the internalization of EVs in G7 renal CSCs 
by fluorescent microscopy, EVs were labelled with 1 
μM Dil dye (Thermo Fisher Scientific, Waltham, MA, 
USA) as described previously [52]. Briefly, purified EVs 
were resuspended in PBS supplemented with 1 μM Dil 
dye and ultracentrifuged at 100,000 g for 1 h at 4 °C. 
Following labelling, the EVs were washed with PBS 
by ultracentrifugation as mentioned above. The pellet 
obtained was then resuspended in RPMI with 1% DMSO 
and frozen for subsequent studies.
Co-administration of HLSC-EVs and TKIs 
increase apoptosis of rCSCs
Renal CSCs were incubated with EVs derived from 
MSC or HLSCs.
For loading experiments, EVs were loaded with 
10 μM of Sunitinib or 50 μM of Sorafenib by incubating 
together for 15 minutes at 37°C and then ultracentrifuged 
at 100,000 g for 1 h at 4°C to remove the unloaded drug. 
EVs were resuspended in RPMI with 1% DMSO and 
named EV-SUN those loaded with Sunitinib or EV-SOR 
those loaded with Sorafenib. The supernatant (surn-SUN 
and surn-SOR) was recovered and used in the experiments 
as negative control. The dose of Sunitinib and Sorafenib 
used was chosen on the base of preliminary experiments 
showing 8-10% of drug incorporation, as described [53]. 
Spectrum analysis was used to evaluate the effective drug 
loading within EVs and it revealed the presence of 1.8 μM 
Sunitinib and 10 μM for Sorafenib in EV-SUN or EV-SOR 
(not shown).
Apoptosis assay
Apoptosis was evaluated by Muse™ Annexin 
V and Dead Cell Assay (Millipore, Merck KGaA, 
Darmstadt, Germany) according to manufacturer’s 
instructions. The assay is based on the detection of 
phosphatidylserine (PS) on the surface of apoptotic 
cells, using fluorescently labeled Annexin V in 
combination with the dead cell marker, 7-AAD. 
Briefly, G7 renal CSCs or C10 breast CSCs were 
seeded at the concentration of 2×104 cells/well and, 
after cell attachment, were stimulated with HLSC-
EVs or Sunitinib or Sorafenib alone or in combination 
and cultured for 48 hours. At the end of the incubation 
period, the supernatant containing dead cells and cells 
were recovered, incubated for 20 minutes with Annexin 
V/7-AAD reagent and read at Muse. The results were 
showed as the percentage of total apoptotic cells.
Immunofluorescence
For immunofluorescence experiments, renal CSCs 
were seeded at the concentration of 2×104 cells/well and, 
after cell attachment, were stimulated with HLSC-EVs 
(50×103/target cells) or Sunitinib alone or in combination 
and cultured for 48 hours. At the end of the incubation 
time, cells were stained with Annexin V/7-AAD reagent 
for 20 minutes at room temperature in the dark. Then, 
cells were washed and paraformaldehyde fixed. Nuclei 
were stained with Hoechst 33342. Microscopy analysis 
was performed using a LSM5 Pascal confocal microscope 
(Carl Zeiss International).
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Phospho-protein array
Intracellular phosphoproteins were evaluated in 
the lysates of renal G7 CSCs by the magnetic bead-
based immunoassays Bio-Plex Pro cell-signaling assay 
according to manufacturer’s instruction (BIoRad, 
Hercules, California, US). Briefly, cells were treated 
or not with Sunitinib (1 μM) or Sorafenib (5 μM) or 
HLSC-EVs (50 × 103 EV/target cell) or with the co-
administration of HLSC-EVs/Sunitinib or HLSC-EVs/
Sorafenib for three hours. Then, cells were lysed and 
lysates were incubated with capture antibodies coupled 
to the beads. Coupled beads react with the sample 
containing the analyte of interest. After a series of washes 
to remove unbound protein, a biotinylated detection 
antibody was added to create a sandwich complex. The 
final detection complex was formed with the addition 
of streptavidin-phycoerythrin (SA-PE) conjugate and 
submitted to Bio-Plex system with Bio-Plex Manager 
software analysis.
Western blot analysis
G7 renal CSCs were stimulated for 3 hours with 
HLSC-EVs alone or in combination with Sunitinib or 
Sorafenib. In the sequential administration experiments, 
G7 renal CSCs were stimulated for 3 hours with HLSC-
EVs before or after treatment with Sorafenib (5 μM, 40 
hour stimulation). At the end of incubation time, cells 
were lysed in RIPA buffer supplemented with protease 
and phosphatase inhibitor cocktail and PMSF (Sigma-
Aldrich). Aliquots of the cell lysates containing 30 μg 
proteins form cells or 10 μg from EVs, as determined by 
the Pierce™ BCA Protein method (Thermo Scientific, 
Rockford, IL, USA), were run on 4-20% SDS-PAGE 
under reducing conditions and blotted onto PVDF 
membrane filters using the iBLOT system (Life 
Technologies). The membranes were blocked in Tris-
buffered saline-Tween (TBS-T; 25 mM Tris, pH 8.0, 150 
mM NaCl, and 0.05% Tween-20) containing 5% (w/v) 
non-fat dried milk for 1 h. After blocking, membranes 
were probed overnight with primary antibody. Anti-
vinculin (Santa Cruz Biotechnology), anti-AKT or anti 
p-AKT (Ser473), anti-PTEN or anti-pPTEN, anti-mTOR 
or anti-p-mTOR, anti-Creb or anti-pCreb and anti-Erk 
1/2 (all from Cell Signalling) primary Abs were used. 
After extensive washings with TBS-T, the blots were 
incubated with appropriate peroxidase conjugated 
secondary antibodies for 1 h at room temperature. 
Goat anti-Rabbit IgG and goat anti-mouse IgI HRP 
conjugated secondary antibodies (Thermo Scientific, 
Rockford, IL, USA) were used. Following incubation, 
the membranes were washed extensively with TBS-T, 
probed with ClarityTM Western ECL substrate (Bio-rad, 
CA, USA), and detected by the Chemidoc system (Bio-
rad, CA, USA).
Statistical analysis
All data of different experiments were expressed as 
mean ± SD. Statistical analysis was performed by ANOVA 
with Newmann Keuls’ multicomparison post hoc test. 
Two-tailed p value ≤ 0.05 was considered statistically 
significant.
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